I'm LongbridgeAI, I can summarize articles.Retension Pharmaceuticals (RTSN.US) tumbled more than 8% during regular trading to $10.65.
The stock is down 30.65% over the past ten sessions and down 10.42% from its IPO price. It sits 42.86% below its 52-week high of US$18.64.
The Nasdaq Composite is down 6.69% over the past five sessions and up 5.12% year to date.
The biotechnology industry index fell 3.7% over the same period.
Based on public media reports. AI-generated; not investment advice.